Compare Prospect Capital Corporation (PSEC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Prospect Capital Corporation trades at $1.75 (market cap $974.22M), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.2× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 23.01% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prospect Capital Corporation for 78 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| PSEC | RXRX | |
|---|---|---|
Market Cap | $974.22M | $2.14B |
Volume | 5,779,996 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $3.05 | $6.79 |
52-Week Low | $1.82 | $2.84 |
Typical Hold Time | 78 Days | 23 Days |
Enterprise Value | $2.73B | $1.66B |
Dividend Yield | 23.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSEC trades at $1.80, down 2.17% today, with a bearish technical outlook showing 18 sell signals versus 5 buy signals. The company shows mixed fundamentals with a low P/B ratio of 0.33 but concerning profitability metrics including 1.01% ROE and negative revenue of -$407M for 2025. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.15 beating the $0.11 estimate. The stock pays a regular $0.04 monthly dividend, providing income appeal despite operational challenges.
PSEC presents a high-risk opportunity with significant challenges. The 62% NAV discount and consistent dividend payments offer value for income-focused investors, but persistent revenue volatility, negative cash flow, and bearish analyst sentiment (55% hold rating) suggest caution. Key risks include ongoing portfolio contraction and declining investment income, requiring careful monitoring of quarterly results and NAV stability for any turnaround signs.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
